ACME UNITED CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACME UNITED CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.54M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $194.49M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $191.50M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $193.96M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $182.09M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $164.00M | Mar 30, 2022 |
| FY2019 | Dec 31, 2019 | $33.87M | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | $37.00M | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | $40.22M | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | $31.37M | Mar 13, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.41M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $76.35M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $72.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $63.56M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $64.80M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $59.59M | Mar 30, 2022 |
| FY2019 | Dec 31, 2019 | $12.29M | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | $13.13M | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | $14.77M | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | $11.80M | Mar 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.18M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $10.02M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $17.79M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $3.03M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $13.66M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $8.10M | Mar 30, 2022 |
| FY2019 | Dec 31, 2019 | $978.0K | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | $1.06M | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | $2.67M | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | $807.0K | Mar 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.72M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.14M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $13.19M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $6.27M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $12.77M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $11.41M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $8.43M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $7.46M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $7.88M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $8.44M | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $251.0K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $596.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $734.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $752.0K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $750.0K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $690.0K | Mar 10, 2017 |
| FY2015 | Dec 31, 2014 | $665.0K | Mar 11, 2016 |
| FY2014 | Dec 31, 2013 | $603.0K | Mar 6, 2015 |
| FY2013 | Dec 31, 2012 | $573.0K | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $535.5K | Mar 8, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.69M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $62.21M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $59.02M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $57.29M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $52.03M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $48.18M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $43.57M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $43.19M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $40.02M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $37.11M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.23M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $11.98M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $28.90M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $2.89M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $5.14M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $5.72M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $14.70M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.48M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.81M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $8.86M | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.65M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $7.15M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.67M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $4.30M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $6.37M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $2.57M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.68M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.85M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.15M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.81M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.00M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $162.17M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $149.24M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $164.38M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $144.44M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $129.87M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $110.75M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $109.48M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $114.73M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $92.07M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.39M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $55.19M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $51.34M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $85.35M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $67.36M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $67.15M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $55.04M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $57.15M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $64.79M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $45.95M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.61M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $106.98M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $97.90M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $79.03M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $77.08M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $62.72M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $55.70M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $52.33M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $49.94M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $46.12M | Mar 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.91M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $9.91M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $8.19M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $8.19M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.80M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $4.80M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $4.70M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.70M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.70M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.95M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.29M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $94.50M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $86.72M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $70.97M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $69.87M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $58.03M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $51.57M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $47.55M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $44.47M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $41.86M | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.60M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $6.40M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.80M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $6.10M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.84M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $4.17M | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $6.82M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $4.41M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $9.34M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $5.91M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 4 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 3 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 2 | Mar 30, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 4 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 3 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 2 | Mar 30, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.81M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 3.75M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 3.65M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 3.54M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 3.52M | Mar 10, 2023 |